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Abstract
Background: Cancer/testis antigens are considered potential targets for immunotherapy due to their tumor-
associated expression pattern. Although recent studies have demonstrated high expression of CT45 in classical
Hodgkin’s lymphomas (cHL), less is known about the expression pattern of other families of CTAs in cHL. We aim
to evaluate the expression of MAGE-A family, MAGE-C1/CT7, MAGE-C2/CT10, NY-ESO1 and GAGE family in cHL and
to correlate their expression with clinical and prognostic factors in cHL.
Methods: Tissue microarray was generated from 38 cHL archival cases from Pathology Department of Universidade
Federal de Sao Paulo. Immunohistochemistry (IHC) was done using the following panel of antibodies: MAGE-A family
(MA454, M3H67, 57B and 6C1), GAGE (#26), NY-ESO-1 (E978), MAGE-C1/CT7 (CT7-33) and MAGE-C2/CT10 (CT10#5).
Results: We found CTA expression in 21.1% of our cHL series. Among the tested CTAs, only MAGE-A family 7/38
(18.4%) and MAGE-C1/CT7 5/38 (13.2%) were positive in our cHL samples. We found higher CTA positivity in
advanced stage (28.6%) compared to early stage (11.8%) disease, but this difference was not statistically significant.
Analysis of other clinicopathological subgroups of cHL including histological subtypes, EBV status and response to
treatment also did not demonstrate statistical significant differences in CTA expression.
Conclusion: We found CTA expression in 21.1% of cHL samples using our panel. Our preliminary findings suggest
that from all CTAs included in this study, MAGE-A family and MAGE-C1/CT7 are the most interesting ones to be
explored in further studies.
Keywords: Hodgkin?’?s Lymphoma, cancer/testis antigens
Background
Classical Hodgkin lymphoma (cHL) is characterized by
the presence of rare neoplastic Hodgkin-Reed-Sternberg
(HRS) cells embedded in an inflammatory background
of nonmalignant cells [1,2]. The mechanisms of how
HRS cells survive in this inflammatory milieu remain
controversial and the identification of specific antigens
restricted to the HRS cells is crucial for the develop-
ment of new treatment strategies, augmenting host anti-
tumor immunological response.
Cancer/testis antigens (CTAs) are considered potential
candidates for antigen-specific cancer immunotherapy
due to their particular characteristics of high immuno-
genicity with no or highly restricted expression in nor-
mal tissues (testis and placenta) [3]. There are more
than 100 CTA genes reported in the literature to date
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understood. Recent studiesh a v ep r o v i d e ds o m ee v i -
dence that CTAs may have antiapoptotic properties
rather than regulating cell proliferation or adhesion in
cancer [5-12] and it could explain the persistence of
minimal residual disease in some malignancies, even in
cHL, where the potential of cure is very high. The fre-
quency of CTA expression is highly variable among dif-
ferent tumor types. Melanoma, ovarian cancer, and lung
cancer are considered tumors with high frequency of
CTA expression, while hematopoietic malignancies,
renal, colon and pancreatic cancers, are considered
tumors with low frequency of CTA expression [3].
Some exceptions to this observation among hemato-
poietic malignancies are the high expression of CT7/
MAGE-C1 in multiple myeloma [13,14], and CT45 in
classical Hodgkin lymphoma (cHL) [15,16]. Studies cor-
relating CTA expression with clinicopathological fea-
tures in different tumor types have demonstrated the
association of CTA positivity with higher tumor grade,
advanced stage or metastatic disease and worse clinical
outcome [13,17-25].
Considering that the available information about CTA
expression in cHL is scarce and heterogeneous regard-
ing methods and samples, we investigated the immuno-
histochemical expression against a broad panel of CTAs
in cHL tissue samples to evaluate their potential as
prognostic markers and candidates for immunothera-
peutic approach in cHL patients.
Methods
We retrospectively reviewed all cases of cHL diagnosed
between 2004 and 2008 at the University Hospital São
Paulo. Medical records from 38 adult patients (> 18
years) with cHL were reviewed and information on sex,
age at diagnosis, Ann Arbor clinical stage, laboratory
results, treatment used and response were retrieved. The
response to primary treatment was classified according
to the International Workshop criteria [26]. Patients
treated with radiotherapy alone as first-line therapy and
with positive HIV serology were excluded from this
study. For this study, only cHL patients with tumors
whose histology could be confirmed by hemopathologist
re-review and paraffin blocks with enough material for
tissue microarray (TMA) construction could be retrieved
were studied. Sufficient data was obtained from 38
patients. All patients received ABVD (doxorubicin, bleo-
mycin, vinblastine and dacarbazine) chemotherapy pro-
tocol and had locally extensive or advanced stage
disease at diagnosis. Locally extensive disease was
defined by clinical stages I-II-A/B (Ann Arbor Staging
System) with massive mediastinal adenopathy (mass >
1/3 maximum intrathoracic diameter on standing pos-
tero-anterior chest x-rays), and advanced disease defined
as stages III-IV. Determination of EBV-association in
tumor biopsies was done by immunohistochemistry for
latent membrane protein 1 (LMP1) following previously
established procedures [27]. Samples from a known
EBV-related cHL served as a positive control in each
run.
This research was approved by the Ethical Review
Committee of our Institution according to the Declara-
tion of Helsinki (0998/07), and all patients provided
written informed consent.
Formalin-fixed paraffin embedded tissues of 38 cHL
were obtained from the archives of the Department of
Pathology, Hospital São Paulo, UNIFESP, Brazil. All HL
cases were classified according to WHO classification
for hematologic malignancies [28] as cHL. 25 (65.8%)
cases were classified as nodular sclerosis subtype, 9
(23.7%) as mixed cellularity, 2 (5.3%) as lymphocyte pre-
dominant and 2 (5.3%) were unclassified. Table 1 sum-
marizes the clinical data of these patients. Slides from
all cases were reviewed and representative blocks were
chosen for tissue microarray.
Two core-needle biopsies (1.0 mm diameter) from
tumor representative areas of each HL case were
obtained and then re-embedded in an array master
block using techniques originally developed by Kononen
et al. [29] and then modified by Hedvat et al. [30] and
Beecher Instruments (Sun Prairie, WI, USA) arraying
device.
The mAbs used for immunohistochemistry are listed
in Table 2 [22,31-38]. The evaluation of MAGE-A
family expression was done using a “MAGE-A cocktail”
Table 1 Clinical data of Hodgkin’s lymphoma patients (n
= 38).
Clinical data n %
Median age: 28.5 (16-57)
Gender
Male 18 47.4
Female 20 52.6
HL Subtype
Nodular sclerosis 25 65.8
Mixed cellularity 9 23.7
Lymphocyte predominant 2 5.3
Unclassified 2 5.3
Ann Arbor staging
Early (I or II) 17 44.7
Advanced (III or IV) 21 55.3
EBV status
Negative 21 55.3
Positive 17 44.7
Response
Complete response 30 78.9
Relapsed/refractory 8 21.1
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Page 2 of 6containing the following antibodies: MA454, M3H67, 57B
and 6C1, that allowed an overview of MAGE-A family
(MAGE-A1, MAGE-A2, MAGE-A3, MAGE-A4, MAGE-
A6 MAGE-A10 and MAGE-A12) expression in HL.
Testis with preserved spermatogenesis was used as
positive controls and reactive lymph nodes and tonsils
samples were used as negative controls for all
antibodies.
Associations between the variables were tested by the
Pearson Chi-Square Test (X
2). Mann-Whitney test was
used to perform mean comparisons. A p value lower
than 0.05 was considered as statistically significant.
Results
The majority of patients presented advanced disease and
B symptoms at diagnosis. We found a strong correlation
between anti-LMP1 identification on HRS cells and
response to ABVD regimen, with all 21 EBV-negative
patients achieving complete response (CR) and only 9/
17 (52.9%) of EBV-positive patients achieving CR (p <
0.001). None of other clinical subgroups presented sta-
tistical significant difference in treatment response, as
demonstrated on Table 3.
Due to the low overall CTA expression in cHL TMA,
positivity was not graduated, and the samples were ana-
lyzed as positive (any degree of positivity) or negative.
Figure 1 demonstrates three nodular sclerosis cHL sam-
ples stained for CT7. Sample (A) shows diffuse positiv-
ity, sample (B) is focally positive and sample (C) is a
negative case.
E i g h t( 2 1 . 1 % )o f3 8c H Lc a s e se x p r e s s e da tl e a s to n e
CTA, being 6/25 nodular sclerosis and 2/9 mixed cellu-
larity. Among the 8 positive cases, 6/20 were female and
2/18 male. Despite the difference found in CTA expres-
sion between early (11.8%) and advanced stage (28.6%)
disease, this difference was not statistically significant (p
= 0.195). None of the other clinical subgroups of cHL
according to histological subtypes, EBV status and
response to treatment also presented statistically signifi-
cant difference in CTA expression, as demonstrated on
Table 4. Among the tested CTAs, only MAGE-A family
7/38 (18.4%) and MAGE-C1/CT7 5/38 (13.2%) were
positive in our cHL samples. CT10/MAGE-C2, GAGE
and NY-ESO-1 were negative in all samples. Four of
these samples were positive for both CTAs.
Discussion and conclusions
In our study, the majority of cases had B symptoms
(68.4%) and advanced disease (65.7%) at diagnosis, as
Table 2 Monoclonal antibodies used in immunohistochemical analyses.
Monoclonal
antibody
Mainly recognized
Antigen(s)
Source Cellular staining
pattern
References
MA454* MAGE-A1 LICR Cytoplasmic [22,31-34]
M3H67* MAGE-A3 LICR Nuclear & cytoplasmic [22,33,34]
57B * MAGE-A4 Dr Spagnoli, Basel, Switzerland Nuclear & cytoplasmic [22,33,34]
6C1* MAGE-A 1, 2, 3, 4, 6, 10 and 12 LICR Nuclear & cytoplasmic [35]
CT7-33 CT7/MAGE-C1 LICR Nuclear & cytoplasmic [22,33,34]
CT10#5 CT10/MAGE-C2 LICR Nuclear [35-37]
#26 GAGE BD Bioscience Nuclear & cytoplasmic [35,36]
E978 NY-ESO-1 LICR Cytoplasmic [36,38]
*MAbs included in “MAGE-A cocktail” used to search MAGE-A family expression in HL TMA.
Table 3 Hodgkin’s lymphoma treatment response
analysis.
Clinical data N Complete
response
(%)
N Refractory/
relapsed
(%)
p
value
Gender
Male 13 72.2 5 27.8 0.286
Female 17 85.0 3 15.0
HL Subtype
Nodular sclerosis 21 84.0 4 16.0 0.220
Mixed cellularity 5 55.6 4 44.4
Lymphocyte
predominant
2 100.0 0 0
Unclassified 2 100.0 0 0
Ann Arbor staging
Early (I or II) 15 88.2 2 11.8 0.195
Advanced (III or IV) 15 71.4 6 28.6
EBV status
Negative 21 100.0 0 0 <
0.001
Positive 9 52.9 8 47.1
CTA positivity
0 CT 24 80.0 6 20.0 0.954
> or = 1 6 75.0 2 25.0
MAGE-A
negative 24 77.4 7 22.6 0.538
positive 6 85.7 1 14.3
CT7
negative 27 81.8 6 18.2 0.279
positive 3 60 2 40
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EBV was 44.7% in our cohort of cHL. According to lit-
erature, the incidence of EBV-related cHL is highly vari-
able among different populations and higher EBV
positivity has seen in underdevelopment countries com-
pared to developed ones. In previous studies, Oliveira et
al. and Vassallo et al. found EBV positivity in 52.5% and
64.1% of Brazilian cHL patients respectively [39,40]. The
prognostic significance of EBV expression is controver-
sial, but the correlation of EBV positivity and poorer
outcome has been described in some studies [41]. The
difference of treatment failure rate between EBV positive
(47.1%) and EBV negative patients (0%) was statistically
significant (p < 0.001) in our cohort.
Using our panel, we found expression of CTAs in
21.1% of cHL patients. MAGE-A family was positive in
18.4% and MAGE-C1/CT7 in 13.2% of samples. Despite
the availability of few studies evaluating the expression of
CTAs in cHL to date, our findings are in agreement with
most of studies that evaluated the expression of same
CTAs in cHL using RT-PCR or immunohistochemical
analysis. Expression of MAGE-A family in cHL was eval-
uated by Chambost et al. [42] and it was positive in 28%
of cHL samples using RT-PCR and in 21% cHL tissue
sections using immunohistochemistry with an anti-
MAGE-A4 antibody. Recently, Chen et al. [15] described
the expression of CT45 in cHL and other B-cell lympho-
mas. They found expression of CT45 in 58% of cHL by
immunohistochemistry. A previous study published by
Heidebrecht et al. [16] also described the expression of
CT45 in 55% of pediatric and adolescent cHL using
immunohistochemistry, reinforcing CT45 as one of the
most promising CTA to be explored in cancer vaccine
trials for cHL to date. Unfortunately, CT45 could not be
included in our immunohistochemistry panel because
specific antibodies were not commercially available,
n e i t h e ra tL u d w i gI n s t i t u t ef o rC a n c e rR e s e a r c h-N Y ,
our collaborating center at the time of this study.
Another CTA family whose expression pattern was stu-
died in cHL was SSX. Colleoni et al. [43] found positivity
of SSX family in 15.6% of 32 cHL samples. In summary,
except for CT45, the available studies suggest an overall
positivity for other CTA families tested in cHL of about
1 0 %t o3 0 % .W ef o u n dat e n d e n c yt oah i g h e rC T A
expression among advanced stage disease compared to
early stage disease in our cHL samples as described in lit-
erature [13,17-25], but the difference did not reach statis-
tical significance.
Therefore, our results emphasize the importance of
studying CTAs expression in a Brazilian set of patients.
We acknowledge the fact that our small sample size
may have influenced these results, and larger studies
are warranted. However, our results point toward a
relationship between CTA expression and disease
severity.
Further studies investigating CTA expression on HRS
cells and how they can elicit humoral and cytotoxic
response will contribute not only to our understanding
on the pathogenesis of cHL but also to the development
Figure 1 Immunohistochemical staining of three different nodular sclerosis cHL samples using an anti-CT7 antibody (CT7-33).( A )
Diffuse positivity. (B) Focal positivity. (C) Negative staining for CT7-33; ×400.
Table 4 Hodgkin’s lymphoma CTA expression analysis.
Clinical data N 0 CTA
(%)
N > or = 1 CTA
(%)
p
value
HL Subtype
Nodular sclerosis 19 76.0 6 24.0 0.752
Mixed cellularity 7 77.8 2 22.2
Lymphocyte predominant 2 100.0 0 0
Unclassified 2 100.0 0 0
Ann Arbor staging
Early (I or II) 15 88.2 2 11.8 0.195
Advanced (III or IV) 15 71.4 6 28.6
EBV status
Negative 17 81.0 4 19.0 0.522
Positive 13 76.5 4 23.5
Treatment Response
Complete response 24 80.0 6 20.0 0.954
Non Complete response 6 75.0 2 25.0
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Page 4 of 6of new CTA-directed immunotherapy, particularly for
advanced stage cases and for patients who did not
achieve a complete response after initial therapy.
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